The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).
 
Aly-Khan A. Lalani
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche/Genentech; Tersera
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Pfizer; Roche/Genentech; Tersera
Research Funding - Bristol-Myers Squibb (Inst); Ipsen; Novartis; Roche
 
Anand Swaminath
No Relationships to Disclose
 
Gregory Russell Pond
Employment - Roche Canada (I)
Stock and Other Ownership Interests - Roche Canada (I)
Consulting or Advisory Role - Bayer; Takeda
 
Anil Kapoor
No Relationships to Disclose
 
William Chu
No Relationships to Disclose
 
Jonathan L. Bramson
Leadership - Triumvira Immunologics, Inc
Stock and Other Ownership Interests - Triumvira Immunologics, Inc
Research Funding - Triumvira Immunologics, Inc
Patents, Royalties, Other Intellectual Property - I have a number of patents pending that have been licensed to Turnstone Biologics and Triumvira Immunologics.
Travel, Accommodations, Expenses - Triumvira Immunologics, Inc
 
Michael G. Surette
No Relationships to Disclose
 
Mark Norman Levine
Honoraria - Bayer
Speakers' Bureau - Bayer
 
Sebastien J. Hotte
Honoraria - Astellas Scientific and Medical Affairs Inc; Bayer; Eisai; Janssen Oncology
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Janssen; Merck; Pfizer; Roche Canada
Research Funding - AstraZeneca; Ayala Pharmaceuticals; Bayer; Bristol-Myers Squibb; Clovis Oncology; Janssen Oncology; Merck; Pfizer (Inst); Roche/Genentech
Travel, Accommodations, Expenses - Eisai